Woodcliff Lake, N.J., May 7, 2014 – Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Friday, May 16, 2014 at 9:30 a.m. EDT to review its results of operations for the first quarter ended March 31, 2014. Par is privately held and currently makes certain financial information available to the public in its filings with the Securities and Exchange Commission. Par will file its financial statements for the quarter ended March 31, 2014 with the SEC prior to the call.

Only holders of Par’s debt securities, certain prospective holders of Par’s debt securities and research analysts who cover or intend to cover Par and its debt securities may participate in the conference call by requesting access to the secured area of Par’s website at http://www.parpharm.com/financialinfo for dial-in information.

About Par Pharmaceutical Companies
Par Pharmaceutical Companies, Inc. is a privately-held, U.S.-based specialty pharmaceutical company. Through its wholly-owned subsidiary’s two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets high-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press release and other company information, visit http://www.parpharm.com/.

Contact:
Stephen Mock
Par Pharmaceutical Companies, Inc.
(201) 802-4033